Condition: Focal Epilepsy With and Without Secondary Generalization · Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response among adult patients affected by focal epilepsy not adequately controlled despite a history of 2 or 3 ASMs before starting treatment with cenobamate (including previous and concomitant ASMs).
This description comes directly from the study's public registry record.
Valeria Tellone · +393452493461 · valeria.tellone@angelinipharma.com
Enrica Salvatori · +39 3458063168 · Enrica.salvatori@angelinipharma.com
Always discuss trial participation with your own doctor first.
| Hôpital TARNIER COCHIN | Paris, France, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716801